港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

719.918

+3.9520.55%

漲家數：15

跌家數：15

平家數：4

市盈率：- -

高：728.504

開：715.966

低：704.159

收：715.966

成交量：1.03億

成交額：37.60億

市值：4,603.13億

流通市值：4,086.12億

資料載入中...

總覽新聞資訊

康諾亞－Ｂ(02162)出現大手買入13.35萬股，成交價$80.0，涉資1.068千萬

阿斯达克财经

榮昌生物(09995)出現大手賣出8.25萬股，成交價$121.0，涉資998.25萬

阿斯达克财经

智通港股早知道 | 國家數據局擬探索詞元交易等新型交易模式央行上調部分銀行境外貸款槓桿率

A股藥企薪酬圖鑑創新藥、CXO、高端醫療器械賽道人均薪酬領先

21世纪经济报道

納斯達克中國金龍指數收漲0.79%

分類定價敲定創新藥概念股飄紅

百濟神州(ONC)小幅拉升至1.39% 陽性胃食管腺癌治療創新藥獲上市受理

和訊信息黃傑：199種創新藥進醫保，震盪行情咋應對？

北京將加快中關村生命科學園三期建設推動AI+醫藥、腦機接口等產業發展

中国新闻网

和訊信息汪基綱：科技高位調整，醫藥消費低位接棒

ETF日報：創新藥板塊的驅動邏輯已經補齊政策一環，構成政策+業績+臨床催化三重共振

勃林格殷格翰與再鼎醫藥宣佈合作開發針對DLL3靶向 T 細胞銜接器和ADC聯合療法，用於治療小細胞肺癌及其他神經內分泌癌

綠葉製藥(02186)創新藥LY03017用於治療阿爾茨海默病精神病性障礙的中國Ⅱ期臨床試驗完成首例受試者入組

科倫藥業：公司出於戰略目的而計劃長期持有海南普利製藥股份有限公司股權

再鼎醫藥與勃林格殷格翰達成協議：將供應靶向Dll3的ADC藥物用於研究，勃林格負責臨床運營主導

勃林格殷格翰與再鼎醫藥宣佈合作開發靶向Dll3的T細胞銜接雙抗與ADC聯合療法用於小細胞肺癌及其他神經內分泌癌

創新藥定價自主權鬆綁！14條舉措健全藥品價格形成機制，釋放了哪些信號

「AI製藥第一股」晶泰科技進駐廣州天河

21世纪经济报道

301189，突然大漲，發生了什麼？創新藥迎來價值迴歸，業績高增長股揭秘

北水動向|北水成交淨買入42.21億北水加倉創新藥概念全天搶籌泡泡瑪特(09992)近8億港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":719.91754,"timestamp":1776413292136,"preClose":715.96594,"halted":0,"volume":103129317,"delay":0,"changeRate":0.005519,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":3.951599,"latestTime":"04-17 16:00:00","open":715.96594,"high":728.5041,"low":704.15936,"amount":3759884233,"amplitude":0.034003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":5.639176,"peRate":-94.270914,"turnoverRate":0.00368,"increases":14,"decrements":17,"flats":2,"marketCap":460313417856,"floatMarketCap":408611897616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":728.5041,"amplitude":0.034003,"preClose":715.96594,"low":704.15936,"pbRate":"5.639176","latestPrice":719.91754,"volume":103129317,"delay":0,"open":715.96594,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":666.249,"twentyDayClose":575.488,"sixtyDayClose":612.872,"secType":"PLATE","market":"HK","turnoverRate":0.00368,"peRate":-94.270914,"marketCap":460313417856,"floatMarketCap":408611897616,"timestamp":1776413292136,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":15,"down":15,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627257113","title":"康諾亞－Ｂ(02162)出現大手買入13.35萬股，成交價$80.0，涉資1.068千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257113","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257113?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 09:54","pubTimestamp":1776304440,"startTime":"0","endTime":"0","summary":"[大手成交]康诺亚－Ｂ(02162)在上午09:54出现大手买入，成交量为13.35万，成交价为港币$80.0，涉资1.068千万。至目前为止，股价升0.883%，今日最高价为$80.0，而最低价为$78.05，总成交量为38.75万股，总成交金额港币$3.087千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604163444/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604163444/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1587","02162","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627408252","title":"榮昌生物(09995)出現大手賣出8.25萬股，成交價$121.0，涉資998.25萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627408252","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627408252?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 09:20","pubTimestamp":1776302400,"startTime":"0","endTime":"0","summary":"[大手成交]荣昌生物(09995)在上午09:20出现大手卖出，成交量为8.25万，成交价为港币$121.0，涉资998.25万。至目前为止，股价升2.282%，今日最高价为$121.0，而最低价为$121.0，总成交量为8.25万股，总成交金额港币$998.25万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26041660/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26041660/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2148510915.USD","LU1064131003.USD","BK0239","BK1583","LU1064130708.USD","LU1969619763.USD","09995","BK1161","688331","LU2328871848.SGD","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627256069","title":"智通港股早知道 | 國家數據局擬探索詞元交易等新型交易模式 央行上調部分銀行境外貸款槓桿率","url":"https://stock-news.laohu8.com/highlight/detail?id=2627256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627256069?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 07:41","pubTimestamp":1776296486,"startTime":"0","endTime":"0","summary":"探索词元交易等新型交易模式，构建以词元为基础，可量化、可定价的数据集价值体系。将进出口银行的境外贷款杠杆率由3上调至3.5。截至收盘，暗盘交易显示报价578港元，较招股价324.2港元上涨78.29%，每手100股，不计手续费，每手赚25380港元。归属于上市公司股东的净利润为207","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SBHMY","LU1807302812.USD","300750","BK4588","03908","BK1516","03750","LU1152091168.USD","08279","BK1147","LU1969619763.USD","SG9999002828.SGD","BK1564","LU0067412154.USD","BK1116","LU0359201612.USD","601995","06656","BK1583","01177","LU0359202008.SGD","LU2328871848.SGD","BK1161","LU1152091754.HKD","02245","09995","BK1574","LU1023057109.AUD","LU0359201885.HKD","BK4585","BK1501","BK1610","BK1190","LU1993786604.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1960683339.HKD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627325669","title":"A股藥企薪酬圖鑑 創新藥、CXO、高端醫療器械賽道人均薪酬領先","url":"https://stock-news.laohu8.com/highlight/detail?id=2627325669","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627325669?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 07:00","pubTimestamp":1776294000,"startTime":"0","endTime":"0","summary":"随着A股年报相继出炉，各企业年薪再次成为焦点。截至2026年4月初，A股已有130家医药生物上市公司完整披露2025年人均薪酬数据。同花顺问财数据显示，医药行业内部薪酬分化极为显著，创新药、CXO、高端医疗器械三大赛道凭借高研发投入与技术壁垒，人均薪酬遥遥领先；而传统仿制药、中药、医药流通等领域则深陷薪酬洼地，行业最高与最低企业年薪差距超8倍。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-16/doc-inhurtwq7427621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399300","BK1583","159883","BK1574","BK1100","09997","CXO","159992","159982","BK1161","06978","09996","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230698","title":"納斯達克中國金龍指數收漲0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230698","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230698?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 04:17","pubTimestamp":1776284255,"startTime":"0","endTime":"0","summary":"嘉楠科技涨8.29%，Tims中国涨6.28%，再鼎医药涨5.74%，BOSS直聘涨5.52%，知乎涨4.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604163706460923.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604163706460923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4170","BK4588","LU2039709279.SGD","ZLAB","BK4509","LU2488822045.USD","BK1588","BK4539","BK4551","BK1161","LU0359202008.SGD","BK4130","BK4600","BK4535","BK4595","NDX",".IXIC","BK4077","LU0359201612.USD","02076","ZH","HK0000252152.HKD","BZ","HK0000500386.USD","09688","HK0000252160.HKD","LU1688375341.USD","BK4503","BK4505","HXC","IE00B29SXG58.USD","BK4563","BK4585","CAN","LU1023057109.AUD","BK1095","BK4526","BK1574","02390"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290255","title":"分類定價敲定 創新藥概念股飄紅","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290255","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290255?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 00:12","pubTimestamp":1776269520,"startTime":"0","endTime":"0","summary":"　　此次《意见》的出台，明确药品价格形成机制以市场为主导，对于新上市的药品引入药品首发价格机制，同时对纳入集采的药品，要健全药品集采价格的形成机制。《意见》强调促进多元支付与价格合理形成，加快商业健康保险创新药品目录落地实施。此外，《意见》还对加强药品价格治理作出部署。　　在政策利好下，4月15日，创新药板块个股多数飘红，博瑞医药（维权）、华人健康等个股股价大涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-16/doc-inhurayu3310975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627423635","title":"百濟神州(ONC)小幅拉升至1.39% 陽性胃食管腺癌治療創新藥獲上市受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2627423635","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627423635?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 23:34","pubTimestamp":1776267252,"startTime":"0","endTime":"0","summary":"金吾财讯 |百济神州(ONC)盘中小幅拉升，截至发稿，报314.69美元，上涨1.39%，成交额1512.97万美元。消息面上，百济神州周一宣布，旗下百赫安®(泽尼达妥单抗)与百泽安®(替雷利珠单抗)针对HER2阳性胃食管腺癌一线治疗的新增适应症上市许可申请，获国家药监局药品审评中心正式受理。有业内分析人士称，该药的上市或有望打破该领域十余年未有实质性突破的治疗僵局。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/Yzk2MTU4OTVjMjIwMzU3MzgyMjUzNg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Yzk2MTU4OTVjMjIwMzU3MzgyMjUzNg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299268","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","LU0588546209.SGD","06978","BK4139","LU1770034418.SGD","688235","LU2328871848.SGD","BK1583","06160","BK4585","BK4526","BK1161","BK1588","IPOS","LU1303224171.USD","LU1969619763.USD","BK0239","BK1574","LU0307460666.USD","BK1500","ONC","BK4588","LU1719994722.HKD","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627523849","title":"和訊信息黃傑：199種創新藥進醫保，震盪行情咋應對？","url":"https://stock-news.laohu8.com/highlight/detail?id=2627523849","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627523849?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 22:06","pubTimestamp":1776261982,"startTime":"0","endTime":"0","summary":"和讯信息黄杰分析，另外我们可以看到15日的消息，工业和信息化部消费品工业司司长在国务院的政策的例行的会议上表示，当前工工信部正在编制医药工业十五五规划的发展，加快创新药打造，加快普惠的医药，还有加快打造数字的医药，加快打造开放医药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260415/32146341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238145","title":"北京將加快中關村生命科學園三期建設 推動AI+醫藥、腦機接口等產業發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238145","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627238145?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:57","pubTimestamp":1776261468,"startTime":"0","endTime":"0","summary":"中新网北京4月15日电(记者吕少威)今后五年，北京回天地区将提升特色优势产业发展能级，加快中关村生命科学园三期建设，推动AI+医药、脑机接口等产业发展。北京市昌平区副区长柳强在15日举行的一场新闻发布会上提到上述内容。发布会上正式发布《进一步推进回龙观天通苑地区提升发展行动计划(2026—2030年)》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706308848.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706308848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","ARTY","CHAT","BK1515","BK0178","BK1574","BK1161","BK0028","BK0075","159938","000931","BK0239","AIPO","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627976280","title":"和訊信息汪基綱：科技高位調整，醫藥消費低位接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=2627976280","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627976280?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:35","pubTimestamp":1776260113,"startTime":"0","endTime":"0","summary":"嗯板块来讲的话，整体还是一个轮动，资金明显有一个高切低，今天领涨的医药、商业航天、消费养殖等等都是相对低位的方向，而跌幅比较大的就是近期机构抱团非常深的这些高景气的科技、算力、PCB等等，但今天这种调整抱团是不是结束了？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260415/32146291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","09939","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627287059","title":"ETF日報：創新藥板塊的驅動邏輯已經補齊政策一環，構成政策+業績+臨床催化三重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2627287059","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627287059?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:20","pubTimestamp":1776259200,"startTime":"0","endTime":"0","summary":"今日A股震荡走弱。上证综指微涨0.01%，报4027.21点，深证成指下跌0.97%，创业板指下跌1.22%，科创综指上涨0.33%。全市场成交额24295亿元，较上日成交额放量327亿元。板块层面，创新药领涨；工业母机、新能源车、半导体设备等跌幅居前。风格层面，小盘弱于大盘，成长弱于价值，双创有所分化。总体而言，今日风险偏好处于偏弱状态。　　展望后市，创新药板块的驱动逻辑已经补齐政策一环，构成政策+业绩+临床催化三重共振。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-04-15/doc-inhuqwta4563290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK1161","BK1574","159992","BK4585","06978","BK4550","FDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230348","title":"勃林格殷格翰與再鼎醫藥宣佈合作開發針對DLL3靶向 T 細胞銜接器和ADC聯合療法，用於治療小細胞肺癌及其他神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230348","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627230348?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:15","pubTimestamp":1776258900,"startTime":"0","endTime":"0","summary":"勃林格殷格翰与再鼎医药启动临床合作，评估双DLL3靶向药物联合疗法在小细胞肺癌及其他神经内分泌癌中的效果。\" Obrixtamig是勃林格殷格翰研发的一款DLL3/CD3双特异性T细胞衔接器，旨在引导人体自身免疫细胞攻击表达DLL3的癌细胞，而DLL3表达是小细胞肺癌及某些神经内分泌癌的标志性特征。Zoci用于小细胞肺癌治疗已获得FDA孤儿药资格及快速通道资格认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4935026_ZH35026_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","BK4526","BK4548","BK1161","09688","ZLAB","BK4080","BK4531","BK1574","BK4585","BK4139","BK4231","BK4588","BK1588","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627335287","title":"綠葉製藥(02186)創新藥LY03017用於治療阿爾茨海默病精神病性障礙的中國Ⅱ期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2627335287","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627335287?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 21:03","pubTimestamp":1776258221,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团自主研发的创新药LY03017用于治疗阿尔茨海默病精神病性障碍的中国Ⅱ期临床试验已完成首例受试者入组。此次开展的中国Ⅱ期临床试验为一项随机、双盲、平行、安慰剂对照研究，旨在评估LY03017治疗阿尔茨海默病精神病性障碍相关幻觉和妄想的初步疗效和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02186","BK1161","BK1606","BK1583","BK1574","06978","159992","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627282874","title":"科倫藥業：公司出於戰略目的而計劃長期持有海南普利製藥股份有限公司股權","url":"https://stock-news.laohu8.com/highlight/detail?id=2627282874","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627282874?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 20:39","pubTimestamp":1776256778,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)04月15日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司持有2000多万的普利制药，都已经退市了 ，为什么还高位买进科伦药业回复：投资者您好，公司出于战略目的而计划长期持有海南普利制药股份有限公司股权。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/15/20260415100624.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/15/20260415100624.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260415/32146086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK0060","BK1191","01477","LU1979443071.USD","LU1064131003.USD","LU1934453819.USD","BK1574","LU1064130708.USD","LU2148510915.USD","002422"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113205164","title":"再鼎醫藥與勃林格殷格翰達成協議：將供應靶向Dll3的ADC藥物用於研究，勃林格負責臨床運營主導","url":"https://stock-news.laohu8.com/highlight/detail?id=1113205164","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113205164?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 20:05","pubTimestamp":1776254727,"startTime":"0","endTime":"0","summary":"再鼎医药有限公司宣布，公司已签署一项合作协议。根据协议条款，再鼎医药将负责提供其靶向Dll3的抗体偶联药物（ADC），用于相关临床研究。而勃林格殷格翰将作为研究的申办方，并全面主导及监督日常临床运营工作的开展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1161","09688","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104176313","title":"勃林格殷格翰與再鼎醫藥宣佈合作開發靶向Dll3的T細胞銜接雙抗與ADC聯合療法 用於小細胞肺癌及其他神經內分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1104176313","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104176313?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 20:03","pubTimestamp":1776254601,"startTime":"0","endTime":"0","summary":"勃林格殷格翰与再鼎医药宣布达成战略合作，将共同开发靶向Dll3的T细胞衔接双特异性抗体与抗体偶联药物的联合疗法。该创新疗法旨在治疗小细胞肺癌及其他神经内分泌癌患者。\n此次合作将整合勃林格殷格翰在肿瘤免疫治疗领域的专业优势与再鼎医药在中国市场的临床开发及商业化能力。双方计划通过联合疗法探索新的治疗模式，为患者提供更具突破性的治疗方案。\n神经内分泌癌是一类罕见且治疗难度较大的恶性肿瘤，小细胞肺癌作为其中最具侵袭性的亚型，长期以来面临治疗选择有限的挑战。靶向Dll3的创新疗法有望为这类患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1588","BK1574","09688","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627428132","title":"創新藥定價自主權鬆綁！14條舉措健全藥品價格形成機制，釋放了哪些信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2627428132","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627428132?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 19:49","pubTimestamp":1776253740,"startTime":"0","endTime":"0","summary":"4月15日，创新药板块走高。　　消息面上，4月14日，国务院办公厅发布《关于健全药品价格形成机制的若干意见》。《意见》提出14条举措，包括优化创新药等新上市药品首发价格机制、发挥医保支付标准对药品价格形成的引导作用、引导药店合理制定药品零售价格、强化短缺药保供稳价等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-04-15/doc-inhuqsma7887286.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-15/doc-inhuqsma7887286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328922","title":"「AI製藥第一股」晶泰科技進駐廣州天河","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328922","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627328922?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 19:30","pubTimestamp":1776252617,"startTime":"0","endTime":"0","summary":"4月15日，AI制药领军企业、“AI制药第一股”晶泰科技正式进驻广州天河的广电平云广场，同时与广州数字科技集团、广东创新投资发展有限公司完成战略签约，共同推动医疗数据与垂类大模型在生物医药领域深度应用。同日，平云OPC创新社区挂牌。晶泰科技由三位麻省理工学院的物理学家于2015年创立，是全球领先的以AI与机器人自动化实验技术驱动研发创新的平台型企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706140328.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706140328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1617","ARTY","BK1141","01477","AGIX","AIPO","BK1574","CHAT","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627285175","title":"301189，突然大漲，發生了什麼？創新藥迎來價值迴歸，業績高增長股揭秘","url":"https://stock-news.laohu8.com/highlight/detail?id=2627285175","media":"数据宝","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627285175?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 18:37","pubTimestamp":1776249420,"startTime":"0","endTime":"0","summary":"在多重利好刺激下，中国创新药商业天花板将显著抬升。　　4月15日，奥尼电子收盘时录得“20cm”涨停板，最新收盘价创历史新高，最新A股市值首次突破100亿元。近年来受行业竞争加剧、下游需求波动等因素影响，公司经营业绩持续下滑。2023年、2024年净利润连续亏损，公司还预计2025年净利润亏损1.45亿元至1.62亿元。2025年中国创新药海外授权交易总额超1300亿美元，创下历史新高。　　微芯生物上涨空间为56.67%，排在首位。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-15/doc-inhuqsky3435564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","301189","BK0214","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627283152","title":"北水動向|北水成交淨買入42.21億 北水加倉創新藥概念 全天搶籌泡泡瑪特(09992)近8億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627283152","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627283152?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 18:17","pubTimestamp":1776248228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月15日港股市场，北水成交净买入42.21亿港元。其中港股通(沪)成交净买入21.28亿港元，港股通(深)成交净买入20.92亿港元。　　北水净买入最多的个股是泡泡玛特、中芯国际、康方生物。北水净卖出最多的个股是阿里巴巴-W、长飞光纤光缆、腾讯。　　北水抢筹创新药概念。花旗发布研报称，药品定价相关意见凸显政府支持信号，恒瑞等创新药企有望受益。　　此外，滴普科技获净买入2048万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260415/32145695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","LU2543165471.USD","SGXZ86797644.SGD","LU0231483743.USD","LU0348766576.USD","LU0359201612.USD","LU0149721374.USD","LU1880383440.USD","LU0348767384.USD","LU1880383366.USD","LU0211977185.USD","LU0593848301.USD","IE0034224299.USD","LU0345775950.USD","LU0588546209.SGD","LU0499858438.USD","LU0164865239.USD","LU0359202008.SGD","09992","LU0531971595.HKD","BK1224","LU0871576103.HKD","SG9999002950.SGD","LU0345776255.USD","SG9999001069.SGD","LU0499858602.USD","LU0307460666.USD","LU1770036033.HKD","LU1023057109.AUD","LU0164880469.USD","PMRTY","LU0359201885.HKD","LU0611395673.USD","LU0823426308.USD","LU0039217434.USD","BK1574","LU0327786744.USD","LU0572944931.SGD","LU0823426480.USD","SGXZ62798434.SGD","LU1481107354.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":3,"totalSize":243,"code":"91000000","status":"200"}]}}